Mastering The Path: Devloping Processes For Successful Clinical-Grade mRNA Manufacturing

As mRNA-based therapeutics continue to advance, developers face increasing pressure to balance product quality, yield, and scalability while meeting the rigorous requirements of clinical-grade manufacturing. Achieving these objectives requires more than platform processes alone. Complex and larger RNA constructs often demand tailored process development strategies that account for construct-specific behaviors throughout production and purification.

Learn how targeted optimization of in vitro transcription (IVT), chromatography, capping, and poly-A tailing can dramatically improve manufacturing performance. Real-world case studies demonstrate how process refinements increased IVT yields by up to 95%, improved recovery rates, and enhanced full-length product integrity for challenging mRNA and self-amplifying RNA constructs. The discussion also highlights the critical role of analytical methods in guiding process development and ensuring product quality.

Discover practical approaches for overcoming common manufacturing bottlenecks, improving critical quality attributes, and building robust, scalable processes that accelerate the path to clinical-grade mRNA production.